Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study

If you haven’t yet had that late-night call from the emergency department about possible meningitis, trust me, it’s coming. And when it does, you’ll realize that neck pain isn’t just for the patients – it’s shared with residents too! But let’s get serious for a moment: bacterial meningitis is a terrifying infection. Back before 2002, we were unsure whether to include steroids like dexamethasone in the treatment. Then came the study by de Gans and van de Beek, clearing up the confusion. Let’s break down what they found…

This multicenter, prospective, randomized, double-blind, placebo-controlled trial recruited 301 adults diagnosed with bacterial meningitis across various European centers. Participants were randomly assigned to receive either dexamethasone (10 mg every 6 hours for 4 days) before or with the first dose of antibiotics, or placebo. The primary outcome was the score on the Glasgow Outcome Scale, assessed 8 weeks after randomization, with scores of 5 (mild or no disability) considered favorable and 1 to 4 unfavorable. Secondary outcomes included death, specific neurological deficits (e.g., hearing loss), and side effects such as gastrointestinal bleeding and hyperglycemia.

Treatment with dexamethasone significantly reduced unfavorable outcomes from 25% to 15% (RR, 0.59; 95% CI, 0.37 to 0.94; p=0.03) and mortality (RR, 0.48; 95% CI, 0.24 to 0.96 P=0.04). In pneumococcal meningitis mortality and unfavorable outcomes were also reduced. Gastrointestinal bleeding actually occurred less in the dexamethasone group.

The 2002 study by de Gans and van de Beek shaped the future of bacterial meningitis treatment by supporting the use of dexamethasone, citing a reduction in mortality and unfavorable outcomes. A subsequent Cochrane review found dexamethasone to be associated with significantly reduced hearing loss but no difference in overall mortality. In line with the European Society of Clinical Microbiology and Infectious Diseases guidelines and Infectious Disease Society of America’s practice guidelines for the management of bacterial meningitis, current clinical practice requires the prompt administration of dexamethasone as soon as a preliminary diagnosis of bacterial meningitis is suspected, alongside the immediate initiation of empiric antibiotics. Ceftriaxone is preferred, with vancomycin added in North America to fight resistant strains. 

Remember that prompt administration of dexamethasone is paramount for the patient! A large systematic review found that a delay of two hours after arrival can result in a twofold increase in mortality and if delayed three hours, a heightened risk of neurological morbidity (OR 1.79, 95% CI 1.03–3.14). Another study revealed that even an hour’s delay can lead to an increase in mortality and morbidity ranging from 13% to 30%. These findings reinforce the urgency and precision required in our clinical response to bacterial meningitis, ensuring the best possible outcomes for our patients.

Hopefully, next time you are called by the Emergency room for someone with neck stiffness and a fever this study will remind you of this important additional component of meningitis patient management!

Feel free to review the original article yourself here!

Check out this pathology image of bacterial meningitis from our website below:

Abundant gray-white exudate surrounding the brainstem and cerebellum secondary to pneumococcal meningitis
Pathology image of the brain and meninges showing abundant gray-white exudate surrounding the brainstem and cerebellum secondary to pneumococcal meningitis

References:

  • Bijlsma MW, Brouwer MC, Kasanmoentalib ES, Kloek AT, Lucas MJ, Tanck MW, van der Ende A, van de Beek D. Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study. Lancet Infect Dis. 2016 Mar;16(3):339-47. doi: 10.1016/S1473-3099(15)00430-2. Epub 2015 Dec 1. PMID: 26652862.
  • de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002 Nov 14;347(20):1549-56. doi: 10.1056/NEJMoa021334. PMID: 12432041.
  • Pajor MJ, Long B, Koyfman A, Liang SY. High risk and low prevalence diseases: Adult bacterial meningitis. Am J Emerg Med. 2023 Mar;65:76-83. doi: 10.1016/j.ajem.2022.12.042. Epub 2022 Dec 28. PMID: 36592564.
  • Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004 Nov 1;39(9):1267-84. doi: 10.1086/425368. Epub 2004 Oct 6. PMID: 15494903.

About the Synopsis Author

Picture of Joshua Lukas, MD

Joshua Lukas, MD

NowYouKnowNeuro Contributor

"Board Pass Guarantee"

Our “Board Pass Guarantee” is designed to provide added confidence and support for users preparing for the ABPN “Initial Certification in Neurology” or ABPN “Continuing Certification in Neurology” examinations. The following terms and conditions apply:

Eligibility

  • The Board Pass Guarantee is only available to users who purchase a 3-month or 1-year subscription to our platform.
  • To qualify for the guarantee, users must complete at least 50% of the question bank associated with their account before the date on which they took the ABPN exam.
  • To qualify for the guarantee, users must have taken the ABPN board exam within 14 months of the purchase of their NowYouKnowNeuro account.
  • This guarantee is effective only for Board exams taken after 07/01/2024.

Guarantee Benefits

  • If a user fails their ABPN “Initial Certification in Neurology” or ABPN “Continuing Certification in Neurology” examination, they will receive an account extension equal to the duration of their original subscription (either 3 months or 1 year).

Proof of Eligibility

  • To claim the guarantee, users must submit an image or screenshot of their official ABPN failure letter. The document must clearly indicate the user’s name, the exam taken, and the result.

Limitations

  • This guarantee does not provide refunds for prior purchases.
  • The guarantee does not cover any fees or costs associated with taking the ABPN exam, including but not limited to registration fees, travel expenses, or other study materials.
  • This guarantee does not apply to other exams beyond the ABPN “Initial Certification in Neurology” or ABPN “Continuing Certification in Neurology” examinations.
  • This guarantee may be used once per person.

How to Claim

  • To request an account extension under the Board Pass Guarantee, users must contact our support team via our Contact Us form within 30 days of receiving their official ABPN failure letter. We will ask for the required proof of eligibility via email as outlined above.

General Terms

  • The Board Pass Guarantee is subject to verification and approval by our team.
    Misrepresentation or submission of falsified documents will result in disqualification from the guarantee and may lead to account suspension.
  • By participating in the Board Pass Guarantee, users agree to these terms and conditions, which are subject to change at our discretion.